Kohjin Bio Co Ltd

Kohjin Bio maintains a strong liquidity position with cash and equivalents of ¥3.15 billion, representing 34.7% of total assets, and a current ratio of 2.04, indicating a solid ability to meet short-term obligations. The company's liquidity FPT score is high, supported by a price-to-book ratio of 1.26 and a debt-to-equity ratio of 0.41, suggesting a conservative capital structure. Profitability metrics show a return on equity (ROE) of 13.75% and a return on assets (ROA) of 8.77%, both exceeding the industry median for pharmaceuticals, which typically ranges between 8-10% ROE and 5-7% ROA. The company's operating margin of 18.05% (¥939.36 million operating income on ¥5.21 billion revenue) is also above the sector average. The company operates through three segments: Tissue Culture, Microbiology, and Cell Processing. The Tissue Culture segment focuses on regenerative medicine and immunotherapy, while the Microbiology segment serves clinical and food testing. The Cell Processing segment provides contract services under the Regenerative Medicine Safety Act. Revenue concentration is not disclosed, but the company's diversified product portfolio suggests moderate exposure to any single market. Growth trajectory is positive, with a current FY outlook indicating a 5.2% revenue increase and a 7.1% EBITDA growth. The next FY is projected to see a 3.8% revenue increase and a 4.9% EBITDA growth, supported by expansion in the regenerative medicine market and increased demand for diagnostic testing. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares in the past 12 months, and the dilution potential remains low. No significant regulatory or geopolitical risks are currently flagged, though the company operates in a highly regulated healthcare environment. Recent events include a 10-K filing disclosing continued investment in R&D for new diagnostic media and cell culture products. No material adverse events or earnings warnings were reported in the latest quarterly transcript.